Episode
Psychedelics and GLP-1s with Arsalan Azam, MD
- Published
- Jul 14, 2026
- Duration seconds
- 2182
- Processing state
not_requested- Canonical source
- https://plantmedicinepodcast.libsyn.com/psychedelics-and-glp-1s-with-arsalan-azam-md
Actions
POST https://stenobird.com/v1/public/podcasts/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/episodes/psychedelics-and-glp-1s-with-arsalan-azam-md/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/psychedelic-medicine-podcast-with-dr-lynn-marie-morski-835820/psychedelics-and-glp-1s-with-arsalan-azam-md.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of the Psychedelic Medicine Podcast, Arsalan Azam, MD joins to unpack the intersection between psychedelics and GLP-1s. Dr. Azam, founder of Daydream MD, completed his residency in Emergency Medicine at the Metropolitan/Harlem Emergency Medicine Residency program in New York before practicing emergency medicine nationwide. Drawing on that experience, he developed a comprehensive ketamine-assisted therapy practice and now blends functional medicine with personalized GLP-1 services to help patients achieve sustainable, biologically tailored health outcomes. In this conversation, Dr. Azam explores the emerging intersection of GLP-1 medications and psychedelic therapies, arguing that both create temporary windows for behavioral change that can be leveraged to improve long-term mental and metabolic health. He explains how GLP-1 medications act primarily on the brain's reward and craving circuits, reducing "food noise" while creating opportunities to reshape habits and addictive behaviors. The discussion also covers how GLP-1s may complement psychedelic-assisted therapies for conditions such as addiction and PTSD, potential interactions with ketamine and classic psychedelics, and important clinical considerations, including nausea, delayed gastric emptying, medication dosing, and the importance of individualized treatment strategies. In this episode, you'll hear: How GLP-1 medications influence the brain's reward, craving, and motivation circuits Why Dr. Azam views GLP-1s and psychedelics as complementary therapies that each create windows for lasting behavioral change The potential role of GLP-1 medications in treating addiction alongside psychedelic-assisted psychotherapy What patients and clinicians should know about combining GLP-1 medications with ketami…